TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

Pharmaceuticals & Biotechnology

₹3331.20-3.80(-0.11%)

Market Open as of Apr 29, 2025, 09:23 IST

What does Torrent Pharmaceuticals Ltd. do?

Pharmaceuticals•Healthcare•Large Cap

Torrent Pharmaceuticals is a prominent pharmaceutical company headquartered in Ahmedabad, India. It operates under the stock ticker TORNTPHARM and boasts a market capitalization of Rs. 104,031.2 Crores.

The company specializes in the research, development, manufacturing, and marketing of generic pharmaceutical formulations, catering to markets not only in India but also in the United States, Brazil, Germany, and other international regions. Its diverse product portfolio spans various therapeutic areas, including:

Cardiovascular
Central Nervous System
Gastro-intestinal
Women's Healthcare
Dermatology
Diabetology
Pain Management
Gynecology
Oncology
Anti-infectives
Vitamins, Minerals, and Nutrients

In addition to these offerings, Torrent Pharmaceuticals extends its expertise through contract manufacturing services.

Originally founded in 1959 as Trinity Laboratories, the company rebranded to Torrent Pharmaceuticals Limited in 1971. It is currently a subsidiary of Torrent Investments Private Limited.

In terms of financial performance, Torrent Pharmaceuticals reported a trailing twelve months revenue of Rs. 11,374 Crores and a profit of Rs. 1,862 crores over the past four quarters. The company has demonstrated substantial growth, with a revenue increase of 33.9% over the past three years.

Torrent Pharmaceuticals is also known for rewarding its investors with dividends, offering a dividend yield of 1.76% per year. In the last twelve months, it distributed a dividend of Rs. 54 per share, showcasing its commitment to returning value to shareholders.

Industry Group:Pharmaceuticals & Biotechnology

Employees:15,718

Website:www.torrentpharma.com

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Category	TORNTPHARM	Pharmaceuticals
PE	60.62	37.19
PS	9.92	5.23
Growth	8.2 %	7.1 %

Valuation
Market Cap	1.13 LCr
Price/Earnings (Trailing)	60.62
Price/Sales (Trailing)	9.92
EV/EBITDA	30.41
Price/Free Cashflow	37.23
MarketCap/EBT	42.77

Fundamentals
Revenue (TTM)	11.37 kCr
Rev. Growth (Yr)	5.3%
Rev. Growth (Qtr)	-1.08%
Earnings (TTM)	1.86 kCr
Earnings Growth (Yr)	13.54%
Earnings Growth (Qtr)	11.04%

Profitability
Operating Margin	23.2%
EBT Margin	23.2%
Return on Equity	24.81%
Return on Assets	12.34%
Free Cashflow Yield	2.69%

Investor Care
Dividend Yield	1.62%
Dividend/Share (TTM)	54
Shares Dilution (1Y)	0.00%
Diluted EPS (TTM)	55.03

Financial Health
Current Ratio	1.21
Debt/Equity	0.41
Debt/Cashflow	1.07

Latest News and Updates from Torrent Pharmaceuticals

Updated Apr 18, 2025

Torrent Pharmaceuticals (TORNTPHARM) has seen a slight uptick in share price, currently trading 1.08% higher at Rs 3,284.75, though the stock has declined 2.19% year-to-date. The increase in holdings by mutual funds and foreign institutional investors indicates a positive outlook. However, the company's P/E ratio remains significantly above the sector average, which could raise concerns among investors. Overall, the mixed performance reflects both optimism and caution in the market.

The Bad News

Mint

The stock has declined 2.19% this year, indicating some challenges.

Mint

Torrent Pharmaceuticals has a TTM P/E ratio of 61.06, significantly above the sector average of 27.35.

Mint

There are 4 sell ratings from analysts, which may indicate some bearish sentiment.

The Good News

Mint

Torrent Pharmaceuticals' share price has gained 1.65% over the past five days.

Mint

Analysts have given Torrent Pharmaceuticals 4 strong buy ratings and 9 buy ratings.

Mint

Both mutual fund and foreign institutional investor holdings have increased compared to the last quarter.

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Shareholder Name	Holding %
TORRENT INVESTMENTS LIMITED (FORMERLY KNOWN AS TORRENT INVESTMENTS PRIVATE LIMITED)	68.31%
MEHTA FAMILY TRUST 1	0%
MEHTA FAMILY TRUST 2	0%
MEHTA FAMILY TRUST 3	0%
MEHTA FAMILY TRUST 4	0%
ANITA SUDHIR MEHTA	0%
SAPNA SAMIR MEHTA	0%
JINAL SUDHIR MEHTA	0%
VARUN SUDHIR MEHTA	0%
SHAAN MEHTA	0%
AMAN MEHTA	0%
SUDHIR UTTAMLAL MEHTA	0%
SAMIR UTTAMLAL MEHTA	0%

Balance Sheet for Torrent Pharmaceuticals

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-13.5%	91	105	81	85	66	65
Current investments	-40%	85	141	234	156	463	184
Loans, current	50%	4	3	3	2	3	3
Total current financial assets	17.7%	2,280	1,937	2,064	2,095	2,300	1,910
Inventories	-8.8%	1,428	1,566	1,577	1,602	1,653	1,797
Total current assets	5.8%	3,958	3,742	3,919	3,926	4,127	3,933
Property, plant and equipment	-2.3%	3,132	3,205	3,113	2,688	2,648	2,620
Capital work-in-progress	21.2%	247	204	235	675	604	544
Goodwill	0%	324	324	324	324	244	244
Non-current investments	25.2%	403	322	218	205	184	184
Loans, non-current	0%	3	3	2	3	2	2
Total non-current financial assets	24%	424	342	238	220	195	220
Total non-current assets	-2.1%	8,450	8,635	8,704	8,946	7,152	7,093
Total assets	0.3%	12,408	12,377	12,623	12,872	11,407	11,153
Borrowings, non-current	-11.9%	1,414	1,604	1,944	2,332	2,242	1,972
Total non-current financial liabilities	-11%	1,442	1,620	1,963	2,360	2,277	1,978
Provisions, non-current	2.5%	289	282	260	245	232	211
Total non-current liabilities	-1.3%	2,525	2,559	2,784	3,007	2,814	2,385
Borrowings, current	-34.8%	1,127	1,729	1,733	2,234	1,050	1,372
Total current financial liabilities	-26.7%	1,978	2,697	2,723	3,183	1,916	2,186
Provisions, current	22.9%	210	171	172	151	132	120
Current tax liabilities	148.3%	73	30	0	-	-	-
Total current liabilities	-21.2%	2,357	2,989	2,974	3,409	2,116	2,422
Total liabilities	-12%	4,882	5,548	5,758	6,416	4,930	4,807
Equity share capital	0%	169	169	169	169	169	85
Total equity	10.2%	7,526	6,829	6,865	6,456	6,477	6,346
Total equity and liabilities	0.3%	12,408	12,377	12,623	12,872	11,407	11,153

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	37.3%	1,146	835	538	508	343	398
Current investments	-40%	85	141	234	156	463	184
Loans, current	50%	4	3	3	2	3	3
Total current financial assets	8%	3,270	3,028	2,699	2,781	2,659	2,391
Inventories	-0.4%	2,271	2,279	2,218	2,230	2,328	2,462
Total current assets	4.8%	5,879	5,611	5,272	5,314	5,218	5,165
Property, plant and equipment	-2.4%	3,217	3,297	3,192	2,772	2,741	2,703
Capital work-in-progress	46.8%	412	281	263	688	609	544
Goodwill	0.3%	339	338	337	338	258	259
Non-current investments	32.3%	42	32	43	43	42	42
Loans, non-current	0%	3	3	2	2	2	2
Total non-current financial assets	-5.6%	68	72	100	94	84	111
Total non-current assets	-2.6%	9,209	9,450	9,457	9,683	7,870	7,805
Total assets	0.2%	15,088	15,061	14,744	15,012	13,219	13,100
Borrowings, non-current	-11.9%	1,414	1,604	2,110	2,496	2,405	2,123
Total non-current financial liabilities	-10.7%	1,497	1,677	2,170	2,570	2,483	2,165
Provisions, non-current	0.2%	446	445	408	393	390	369
Total non-current liabilities	-1.5%	2,737	2,779	3,139	3,367	3,178	2,732
Borrowings, current	-30%	1,634	2,334	2,306	2,801	1,613	1,895
Total current financial liabilities	-12.4%	4,144	4,728	4,362	4,919	3,447	3,863
Provisions, current	8.8%	435	400	405	394	381	411
Current tax liabilities	-46.1%	91	168	8	31	30	42
Total current liabilities	-10.7%	4,847	5,426	4,898	5,447	3,950	4,415
Total liabilities	-7.6%	7,584	8,205	8,037	8,814	7,128	7,147
Equity share capital	0%	169	169	169	169	169	85
Total equity	9.5%	7,504	6,856	6,707	6,198	6,091	5,953
Total equity and liabilities	0.2%	15,088	15,061	14,744	15,012	13,219	13,100

Cash Flow for Torrent Pharmaceuticals

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	1.7%	303	298	236
Change in inventories	-83.4%	37	218	115
Depreciation	13.3%	761	672	602
Impairment loss / reversal	-	0	0	15
Unrealised forex losses/gains	-152.8%	-37	73	-13
Dividend income	-	50	0	0
Adjustments for interest income	-	3	0	3
Net Cashflows from Operations	26.8%	3,218	2,538	2,380
Income taxes paid (refund)	19.6%	325	272	240
Net Cashflows From Operating Activities	27.7%	2,893	2,266	2,140
Cashflows used in obtaining control of subsidiaries	-100.1%	0	1,963	24
Proceeds from sales of PPE	-79.9%	32	155	3
Purchase of property, plant and equipment	-39.8%	344	571	108
Dividends received	-	50	0	0
Interest received	-62.5%	4	9	4
Other inflows (outflows) of cash	111.9%	90	43	-35
Net Cashflows From Investing Activities	87.2%	-296	-2,327	-160
Proceeds from borrowings	-100%	2	2,193	0
Repayments of borrowings	27.2%	1,236	972	1,043
Payments of lease liabilities	0%	5	5	17
Dividends paid	17.6%	1,015	863	677
Interest paid	18.8%	323	272	240
Net Cashflows from Financing Activities	-3322.5%	-2,577	81	-1,977
Net change in cash and cash eq.	0%	20	20	3

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	6%	353	333	255
Change in inventories	-119.6%	-49	256	219
Depreciation	14.3%	808	707	662
Unrealised forex losses/gains	-16%	-57	-49	-36
Adjustments for interest income	-	11	0	0
Net Cashflows from Operations	36.1%	3,764	2,766	2,224
Income taxes paid (refund)	25.2%	498	398	421
Net Cashflows From Operating Activities	37.9%	3,266	2,368	1,803
Cashflows used in obtaining control of subsidiaries	-100.1%	0	1,941	0
Proceeds from sales of PPE	-15.8%	134	159	6
Purchase of property, plant and equipment	-24.6%	433	574	203
Interest received	0%	13	13	7
Other inflows (outflows) of cash	935.7%	118	-13	-8
Net Cashflows From Investing Activities	92.8%	-168	-2,356	-198
Proceeds from borrowings	-100%	0	2,237	219
Repayments of borrowings	40.9%	1,369	972	1,033
Payments of lease liabilities	9.5%	24	22	0
Dividends paid	17.6%	1,015	863	677
Interest paid	22.5%	371	303	258
Net Cashflows from Financing Activities	-3757.9%	-2,779	77	-1,781
Effect of exchange rate on cash eq.	-65%	8	21	1
Net change in cash and cash eq.	199.1%	327	110	-175

Income Statement for Torrent Pharmaceuticals

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-2.3%	2,377	2,434	2,438	2,143	2,123	2,146
Other Income	125%	3	-7	21	76	-11	15
Total Income	-1.9%	2,380	2,427	2,459	2,219	2,112	2,161
Cost of Materials	9.5%	369	337	410	409	376	433
Purchases of stock-in-trade	20.7%	211	175	141	168	129	138
Employee Expense	0%	407	407	406	353	363	366
Finance costs	-11.3%	48	54	64	67	69	77
Depreciation and Amortization	0.5%	191	190	189	195	191	192
Other expenses	-5.6%	539	571	550	536	498	519
Total Expenses	-1.6%	1,729	1,757	1,792	1,689	1,682	1,679
Profit Before exceptional items and Tax	-2.8%	651	670	667	530	430	482
Total profit before tax	-2.8%	651	670	667	530	430	482
Current tax	-10.1%	125	139	117	82	75	83
Deferred tax	-42.9%	41	71	81	38	58	72
Total tax	-21.1%	166	210	198	120	133	155
Total profit (loss) for period	5.4%	485	460	469	410	297	327
Other comp. income net of taxes	73.3%	-7	-29	0	14	-13	-3
Total Comprehensive Income	10.9%	478	431	469	424	284	324
Earnings Per Share, Basic	5.8%	14.33	13.6	13.86	12.12	8.78	9.65
Earnings Per Share, Diluted	5.8%	14.33	13.6	13.86	12.12	8.78	9.65
Debt equity ratio	-	-	-	-	-	-	054
Debt service coverage ratio	-	-	-	-	-	-	0.036
Interest service coverage ratio	-	-	-	-	-	-	0.0866

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	10.9%	8,533	7,695	6,742	6,451	6,168	5,762
Other Income	11.1%	91	82	204	118	237	382
Total Income	10.9%	8,624	7,777	6,946	6,569	6,405	6,144
Cost of Materials	11.9%	1,652	1,477	1,529	1,421	1,353	1,207
Purchases of stock-in-trade	2.6%	548	534	397	399	341	343
Employee Expense	16%	1,451	1,251	1,098	1,097	1,062	1,014
Finance costs	1.7%	303	298	236	339	430	481
Depreciation and Amortization	13.3%	761	672	602	610	607	579
Other expenses	12%	2,061	1,840	1,636	1,487	1,552	1,590
Total Expenses	8.2%	6,707	6,200	5,480	5,203	5,288	5,209
Profit Before exceptional items and Tax	21.6%	1,917	1,577	1,466	1,366	1,117	935
Total profit before tax	21.6%	1,917	1,577	1,466	1,366	1,117	935
Current tax	17.6%	322	274	253	248	192	194
Deferred tax	-5.2%	238	251	222	-20	-14	-4
Total tax	6.7%	560	525	475	228	178	190
Total profit (loss) for period	29%	1,357	1,052	991	1,138	939	745
Other comp. income net of taxes	138%	31	-78	1	110	-115	23
Total Comprehensive Income	42.5%	1,388	974	992	1,248	824	768
Earnings Per Share, Basic	30%	40.1	31.07	29.295	33.62	27.73	22.025
Earnings Per Share, Diluted	30%	40.1	31.07	29.295	33.62	27.73	22.025

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-2.8%	2,809	2,889	2,859	2,745	2,732	2,660
Other Income	288.2%	33	-16	24	31	-33	26
Total Income	-1.1%	2,842	2,873	2,883	2,776	2,699	2,686
Cost of Materials	9.8%	370	337	411	410	379	433
Purchases of stock-in-trade	10%	420	382	313	315	327	292
Employee Expense	1.1%	549	543	550	486	496	503
Finance costs	-11.1%	57	64	75	80	80	91
Depreciation and Amortization	0.5%	199	198	197	203	213	201
Other expenses	-7.7%	673	729	711	697	670	672
Total Expenses	-2.8%	2,151	2,212	2,227	2,145	2,156	2,127
Profit Before exceptional items and Tax	4.5%	691	661	656	631	543	559
Exceptional items before tax	-	0	0	0	0	88	0
Total profit before tax	4.5%	691	661	656	631	631	559
Current tax	-1.9%	153	156	126	142	106	120
Deferred tax	-33.3%	35	52	73	40	82	53
Total tax	-9.7%	188	208	199	182	188	173
Total profit (loss) for period	11.1%	503	453	457	449	443	386
Other comp. income net of taxes	-173.1%	-70	-25	-34	1	-1	-23
Total Comprehensive Income	1.2%	433	428	423	450	442	363
Earnings Per Share, Basic	12.2%	14.88	13.37	13.51	13.27	13.1	11.39
Earnings Per Share, Diluted	12.2%	14.88	13.37	13.51	13.27	13.1	11.39
Debt equity ratio	-	-	-	-	-	-	066
Debt service coverage ratio	-	-	-	-	-	-	0.0359
Interest service coverage ratio	-	-	-	-	-	-	0.0804

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	11.5%	10,728	9,620	8,508	8,005	7,939	7,673
Other Income	29.5%	58	45	197	57	122	57
Total Income	11.6%	10,786	9,665	8,705	8,062	8,061	7,730
Cost of Materials	12%	1,657	1,480	1,538	1,421	1,377	1,290
Purchases of stock-in-trade	8.7%	1,184	1,089	831	1,005	923	846
Employee Expense	18.2%	1,984	1,678	1,526	1,440	1,429	1,404
Finance costs	6.3%	354	333	255	358	451	504
Depreciation and Amortization	14.3%	808	707	662	658	654	618
Other expenses	13.7%	2,690	2,365	2,108	1,933	2,173	2,066
Total Expenses	9%	8,522	7,818	6,994	6,536	6,874	6,811
Profit Before exceptional items and Tax	22.6%	2,264	1,847	1,711	1,526	1,187	919
Exceptional items before tax	-	88	0	-485	0	0	-357
Total profit before tax	27.4%	2,352	1,847	1,226	1,526	1,187	562
Current tax	23.6%	462	374	342	327	221	281
Deferred tax	2.6%	234	228	107	-53	-59	-155
Total tax	15.6%	696	602	449	274	162	126
Total profit (loss) for period	33%	1,656	1,245	777	1,252	1,025	436
Other comp. income net of taxes	111.6%	17	-137	12	100	-192	33
Total Comprehensive Income	51%	1,673	1,108	789	1,352	833	469
Earnings Per Share, Basic	33.9%	48.94	36.79	22.965	36.99	30.275	12.89
Earnings Per Share, Diluted	33.9%	48.94	36.79	0	36.99	30.275	12.89

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical IndustriesPharmaceuticals	4.42 LCr	53.56 kCr	+6.16%	+22.24%	38.52	8.25	+10.28%	+28.38%
CIPLA	CiplaPharmaceuticals	1.26 LCr	27.8 kCr	+7.81%	+10.34%	25.18	4.52	+7.01%	+33.22%
DRREDDY	Dr. Reddy's LabPharmaceuticals	1 LCr	32.07 kCr	+4.76%	-4.14%	18.36	3.12	+14.31%	+4.21%
LUPIN	LupinPharmaceuticals	96.06 kCr	22.19 kCr	+3.82%	+30.29%	33.21	4.33	+13.18%	+59.81%
AUROPHARMA	Aurobindo PharmaPharmaceuticals	72.44 kCr	31.57 kCr	+7.47%	+10.24%	20.77	2.29	+10.80%	+26.04%

TORNTPHARM - Torrent Pharmaceuticals Ltd. Share Price

What does Torrent Pharmaceuticals Ltd. do?

Sector Comparison: TORNTPHARM vs Pharmaceuticals & Biotechnology

Comparative Metrics

Performance Comparison

Valuation

Fundamentals

Profitability

Investor Care

Financial Health

Latest News and Updates from Torrent Pharmaceuticals

The Bad News

The Good News

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Updates from Torrent Pharmaceuticals

Balance Sheet for Torrent Pharmaceuticals

Cash Flow for Torrent Pharmaceuticals

Income Statement for Torrent Pharmaceuticals

Is Torrent Pharmaceuticals Better than it's peers?